Oppenheimer Upgrades Cubist Pharmaceuticals (CBST) to Perform
More News related to CBST
- The Boston Globe names Cubist to Globe 100's Top Places to Work '09
- Cubist Pharmaceuticals to Present at Lazard Capital Markets 6th Annual Healthcare Conference
- Oppenheimer Upgrades Cubist Pharmaceuticals (CBST) to Perform
- Hydra Biosciences and Cubist Form Collaboration to Develop Novel Ion Channel Drugs for Pain Management
- Cubist Pharmaceuticals (CBST) Tops Q3 EPS Views
More News related to Upgrades
- Sprint Nextel (S) Completes Acquisition of Virgin Mobile USA (VM)
- Saks (SKS) Amended and Restates Revolving Credit Agreement
- United Capital Corp. (AFP) Acquires 116,000 Sq Ft Building in Cranbury, New Jersey
- Duke Energy (DUK) Receives $22M US DoE Grant for Wind Energy Storage
- Highlights From AEO's Q3 Conference Call: Comparable Store Sales Declined 5% in First Three Wks of November
Oppenheimer upgrades Cubist Pharmaceuticals (Nasdaq: CBST) from Underperform to Perform. Price target $17.
To see more analyst ratings on CBST Click Here.
Cubist Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.
Related Categories
UpgradesStocks Mentioned
-0.19Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
